Opportunity Information: Apply for W81XWH 21 PRORP CTRA
The Department of Defense (DoD) Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Translational Research Award (CTRA) is a funding opportunity designed to move promising orthopaedic ideas into real-world clinical use, especially where the work is not yet ready for a large, definitive randomized controlled trial. The emphasis is on high-impact clinical research that can realistically change how orthopaedic injuries are diagnosed, treated, rehabilitated, or prevented. Applicants are expected to show how their project could influence standards of care in the near term and over the long term, and how it could strengthen evidence-based guidelines relevant to military Service members, Veterans, and civilian patients dealing with orthopaedic injuries.
A central theme of the CTRA is translation: taking current or emerging techniques, interventions, or clinical approaches and testing or refining them in human clinical settings to better serve military needs. The opportunity highlights outcomes that matter to patients and readiness, such as health, function, and quality of life after injury. Another stated goal is practical decision support, meaning the research should help identify what works best (and for whom) across diagnosis, treatment, rehabilitation, and prevention, with results that are useful not only to clinicians and patients but also to caregivers and policymakers.
This award mechanism is broader than the program’s separate Clinical Trial Award (CTA). The CTA is limited strictly to clinical trials, while the CTRA supports a wider range of clinical research as long as it stays within human-focused clinical boundaries. CTRA projects may be interventional and may include some retrospective analysis, but proposals cannot be purely retrospective or focused only on database mining. Small pilot clinical trials are allowed, which makes this mechanism a fit for early-to-mid stage clinical translation where feasibility, preliminary efficacy, optimization of endpoints, or refinement of clinical protocols still needs to be established before a larger trial is justified. Animal research is explicitly not allowed under this opportunity; applicants needing animal work are directed to a different PRORP mechanism.
The announcement uses the CDMRP definition of clinical research, which includes patient-oriented research involving direct interaction with human subjects (or identifiable human-origin materials), as well as epidemiologic, behavioral, outcomes, and health services research. At the same time, it draws a line around certain types of secondary-use research: studies that fall under IRB Exemption 4 (research using existing, publicly available or otherwise fully de-identified data/specimens) are not considered CDMRP-defined clinical research for this mechanism. In practice, that means investigators need a clear clinical research component involving patients and/or non-exempt human-subjects research activities rather than relying entirely on de-identified datasets.
If a project involves a clinical trial, the opportunity follows the standard definition: human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on health-related outcomes. The announcement also flags regulatory expectations for investigational products. If a study uses a drug that is not FDA-approved for the proposed use, an Investigational New Drug (IND) application may be required, and if required it must be submitted within 12 months of the award date (with documentation from the IRB or FDA if an IND is not needed). Similar requirements apply to investigational devices through an Investigational Device Exemption (IDE), including the possibility of an abbreviated IDE when appropriate. If an investigational product trial will run at international sites, the relevant host-country regulatory submissions must also be made within 12 months. The DoD reserves the right to withdraw funding if required IND/IDE or international regulatory submissions are not made on time, so regulatory strategy and timelines are not a side detail here; they are a core feasibility issue.
Military and Veteran relevance is a required framing element. Every application must clearly explain why the work matters to military and/or Veteran populations affected by orthopaedic injury. Including active-duty Service members or Veterans as participants is encouraged but not mandatory, and collaboration with military or VA clinicians and researchers is also encouraged. Reviewers are looking for projects that speak to combat-related injuries as well as non-battle orthopaedic injuries that still affect readiness, return to duty, and return to work.
The opportunity sets expectations for what a strong application should include. Preliminary data relevant to the proposed clinical research is required, signaling that the DoD wants projects with a credible starting evidence base rather than purely speculative concepts. The study must be grounded in sound scientific rationale supported by a thoughtful review of existing literature. Applicants need to show they can actually execute the study, including real access to an appropriate patient population, a believable accrual plan, and an understanding of how existing standards of care might shape enrollment, comparison groups, and interpretation. If the project uses a drug, device, or other intervention materials, the proposal should document reliable access for the full study duration and address product quality and stability in a way that matches applicable FDA manufacturing expectations (for example GMP and related quality system requirements).
Operational rigor is heavily emphasized. Proposals should present clear objectives and well-justified endpoints or outcome measures, with design choices aligned to Good Clinical Practice (GCP). A detailed statistical analysis plan is expected, along with appropriate statistical expertise on the team and a power analysis tied to sample size projections that can genuinely answer the study questions. Applicants must also include a data management plan and describe the database approach that will protect data integrity; if the research is FDA-regulated, the database must be 21 CFR Part 11 compliant and follow appropriate data standards. In addition, the DoD expects a safety management plan (pharmacovigilance when applicable) and a clinical monitoring plan that explains how compliance and study conduct will be monitored across sites. The announcement also calls for a study coordinator role to shepherd IRB and regulatory processes, coordinate multi-site activities, and manage participant accrual, reflecting the program’s preference for professionally run clinical research operations rather than informal, investigator-only management.
The CTRA also asks applicants to think beyond the grant period. A transition plan is required to show how the intervention, product, or approach would move to the next clinical phase and/or toward market delivery after successful completion. The application should demonstrate strong institutional support or an industry partnership, and when relevant it should identify who will serve as the FDA regulatory sponsor and accept the sponsor responsibilities described in 21 CFR 312. This makes it clear the program is not only funding data collection; it is funding a pathway toward adoption, scale, and real clinical impact.
For funded projects that include a clinical trial, there are additional transparency and registration requirements. Investigators must register applicable trials on ClinicalTrials.gov prior to study initiation, and they must post a copy of the IRB-approved informed consent form on a publicly available federal website as required under federal human subjects regulations (referenced in 32 CFR 219). These requirements align the award with broader federal expectations around trial transparency and participant protection.
On the funding and award structure, the DoD issues these awards as assistance agreements, meaning either grants or cooperative agreements. Which one you receive depends on how much substantial involvement the DoD anticipates during performance. If the agency expects minimal involvement, it will use a grant; if it expects collaboration, participation, or intervention during the work, it will use a cooperative agreement, and the specific involvement will be spelled out in the award terms. For FY21, the anticipated maximum total cost per award for the full period of performance is capped at $1.5 million. Program-wide, the DoD anticipated roughly $7.5 million total to fund about five awards, with selections depending on available funds and the scientific and programmatic merit of submitted applications. The posted timeline notes the original application closing date as September 10, 2021, and indicates awards were expected no later than September 30, 2022, using FY21 funds that would remain available for obligation within the applicable federal funding lifecycle (noted as expiring for use on September 30, 2027).
In plain terms, this opportunity is aimed at clinically grounded orthopaedic research that is ready to be tested with patients, is supported by real preliminary evidence, and is built with the regulatory, statistical, operational, and translational planning needed to produce results that can actually change practice for Service members, Veterans, and the broader orthopaedic patient population.Apply for W81XWH 21 PRORP CTRA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Apr 01, 2021.
- Applicants must submit their applications by Sep 10, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: DoD PRORP Clinical Translational Research Award (CTRA)
What is the PRORP Clinical Translational Research Award (CTRA)?
The Department of Defense (DoD) Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Translational Research Award (CTRA) is a funding opportunity intended to move promising orthopaedic ideas into practical clinical use. It targets projects that are not yet ready for a large, definitive randomized controlled trial, but are far enough along to be tested, refined, or optimized in human clinical settings.
What is the main goal of this award?
The central goal is translation: taking current or emerging techniques, interventions, or clinical approaches and evaluating them in humans to generate evidence that can change clinical practice. The program emphasizes outcomes that matter to patients and military readiness, such as health, function, and quality of life after orthopaedic injury.
What kinds of impact is the DoD looking for?
The announcement emphasizes high-impact clinical research with a realistic path to changing how orthopaedic injuries are diagnosed, treated, rehabilitated, or prevented. Applicants are expected to explain how results could influence standards of care in the near term and the long term, and how the work could strengthen evidence-based guidelines relevant to Service members, Veterans, and civilians with orthopaedic injuries.
How is the CTRA different from the PRORP Clinical Trial Award (CTA)?
The CTA is limited strictly to clinical trials. The CTRA is broader and can support a wider range of human-focused clinical research, including interventional work and some retrospective analysis, as long as the project is not purely retrospective and does not rely solely on database mining.
Are small pilot clinical trials allowed under the CTRA?
Yes. Small pilot clinical trials are allowed, making this mechanism appropriate for early-to-mid stage clinical translation where feasibility, preliminary efficacy, endpoint optimization, or protocol refinement is still needed before a larger trial is justified.
Is animal research allowed?
No. Animal research is explicitly not allowed under this opportunity. Applicants who need animal work are directed to pursue a different PRORP mechanism.
What does the program mean by "clinical research"?
The opportunity uses the CDMRP definition of clinical research. This includes patient-oriented research with direct interaction with human subjects (or identifiable human-origin materials), and can also include epidemiologic, behavioral, outcomes, and health services research, as long as it fits within human-focused clinical boundaries.
Can a study that only uses existing de-identified public data qualify?
Not under this mechanism. Studies that fall under IRB Exemption 4 (using existing, publicly available or fully de-identified data/specimens) are not considered CDMRP-defined clinical research for this opportunity. A proposal needs a clear clinical research component involving patients and/or non-exempt human-subjects research activities, rather than relying entirely on de-identified datasets.
Can proposals include retrospective analysis?
Yes, proposals may include some retrospective analysis. However, the project cannot be purely retrospective and cannot be focused only on database mining.
What qualifies as a clinical trial under this announcement?
If human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on health-related outcomes, the study is considered a clinical trial under the standard definition referenced in the announcement.
What are the IND requirements if a study uses a drug?
If a study uses a drug that is not FDA-approved for the proposed use, an Investigational New Drug (IND) application may be required. If an IND is required, it must be submitted within 12 months of the award date. If an IND is not needed, documentation from the IRB or FDA is expected to support that determination.
What are the IDE requirements if a study uses a device?
Similar expectations apply to investigational devices through an Investigational Device Exemption (IDE), including the possibility of an abbreviated IDE when appropriate. If an IDE is required, the regulatory submission timing expectation (within 12 months of the award date) is part of feasibility.
What if the study includes international sites using investigational products?
If an investigational product trial will run at international sites, the relevant host-country regulatory submissions must also be made within 12 months of the award date.
Can funding be withdrawn for missed regulatory deadlines?
Yes. The DoD reserves the right to withdraw funding if required IND/IDE submissions or required international regulatory submissions are not made on time. The regulatory strategy and timeline are treated as core feasibility issues.
Is military or Veteran relevance required?
Yes. Every application must clearly explain why the work matters to military and/or Veteran populations affected by orthopaedic injury.
Do projects have to enroll active-duty Service members or Veterans as participants?
No. Including Service members or Veterans as participants is encouraged but not mandatory.
Are collaborations with military or VA partners expected?
Collaboration with military or VA clinicians and researchers is encouraged. Reviewers are looking for projects that speak to combat-related injuries and non-battle orthopaedic injuries that affect readiness, return to duty, and return to work.
Is preliminary data required?
Yes. Preliminary data relevant to the proposed clinical research is required, indicating the program expects a credible evidence base rather than a purely speculative concept.
What level of operational planning is expected in the application?
Operational rigor is heavily emphasized. The application is expected to include clear objectives, justified endpoints/outcome measures, Good Clinical Practice (GCP)-aligned design choices, a detailed statistical analysis plan, appropriate statistical expertise, and a power analysis tied to sample size projections that can answer the study questions.
What patient access and accrual information should applicants be prepared to show?
Applicants are expected to demonstrate real access to an appropriate patient population and provide a believable accrual plan. The proposal should also show awareness of how existing standards of care could affect enrollment, comparison groups, and interpretation.
What data management expectations apply?
A data management plan is expected, including a database approach that protects data integrity. If the research is FDA-regulated, the database must be 21 CFR Part 11 compliant and follow appropriate data standards.
Are safety oversight and monitoring plans required?
Yes. The DoD expects a safety management plan (including pharmacovigilance when applicable) and a clinical monitoring plan describing how compliance and study conduct will be monitored across sites.
Is a study coordinator role expected?
Yes. The announcement calls for a study coordinator role to support IRB and regulatory processes, coordinate multi-site activities, and manage participant accrual, reflecting a preference for professionally run clinical research operations.
What are the expectations for access to drugs/devices/intervention materials?
If the project uses a drug, device, or other intervention materials, the proposal should document reliable access for the full study duration. It should also address product quality and stability consistent with applicable FDA manufacturing expectations (such as GMP and related quality system requirements).
Is a transition plan required?
Yes. A transition plan is required to describe how the intervention, product, or approach would move to the next clinical phase and/or toward market delivery after successful completion.
Does the DoD expect institutional support or industry partnership?
Yes. The application should demonstrate strong institutional support or an industry partnership as part of the plan to move beyond the grant period and toward adoption and real-world clinical impact.
Who is expected to serve as the FDA regulatory sponsor, if applicable?
When relevant, the application should identify who will serve as the FDA regulatory sponsor and accept sponsor responsibilities described in 21 CFR 312.
Are there transparency requirements for funded clinical trials?
Yes. For funded projects that include a clinical trial, investigators must register applicable trials on ClinicalTrials.gov prior to study initiation. They must also post a copy of the IRB-approved informed consent form on a publicly available federal website as required under federal human subjects regulations referenced in 32 CFR 219.
What type of award instrument does the DoD use for this opportunity?
Awards are issued as assistance agreements, meaning either grants or cooperative agreements. The choice depends on how much substantial involvement the DoD anticipates during the project.
How does a cooperative agreement differ from a grant in this program?
If the DoD anticipates collaboration, participation, or intervention during performance, it may issue a cooperative agreement and spell out that involvement in the award terms. If minimal involvement is expected, the award may be a grant.
What was the anticipated maximum funding per award (FY21)?
For FY21, the anticipated maximum total cost per award for the full period of performance was capped at $1.5 million.
About how many awards were expected and what was the total program funding (FY21)?
The DoD anticipated roughly $7.5 million total to fund about five awards, depending on available funds and the scientific and programmatic merit of applications.
What timeline details were provided in the announcement?
The posted timeline listed an original application closing date of September 10, 2021, and indicated awards were expected no later than September 30, 2022. The announcement also noted FY21 funds would remain available for obligation within the applicable federal funding lifecycle, with an expiration for use noted as September 30, 2027.
What types of outcomes does the CTRA emphasize?
The opportunity highlights patient- and readiness-relevant outcomes such as health, function, and quality of life after injury. It also emphasizes practical decision support: helping determine what works best (and for whom) across diagnosis, treatment, rehabilitation, and prevention, with results useful to clinicians, patients, caregivers, and policymakers.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: National Unity Project
Previous opportunity: Fiscal Year (FY) 2021 Homeland Security Grant Program (HSGP)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 21 PRORP CTRA
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 21 PRORP CTRA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Peer Reviewed Orthopaedic, Clinical Trial Award Apply for W81XWH 21 PRORP CTA Funding Number: W81XWH 21 PRORP CTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Peer Reviewed Orthopaedic, Applied Research Award Apply for W81XWH 21 PRORP ARA Funding Number: W81XWH 21 PRORP ARA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award Apply for W81XWH 21 OPORP CTA Funding Number: W81XWH 21 OPORP CTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Orthotics and Prosthetics Outcomes, Clinical Research Award Apply for W81XWH 21 OPORP CRA Funding Number: W81XWH 21 OPORP CRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Early Investigator Research Award Apply for W81XWH 21 PCRP EIRA Funding Number: W81XWH 21 PCRP EIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Health Disparity Research Award Apply for W81XWH 21 PCRP HDRA Funding Number: W81XWH 21 PCRP HDRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Idea Development Award Apply for W81XWH 21 PCRP IDA Funding Number: W81XWH 21 PCRP IDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Translational Science Award Apply for W81XWH 21 PCRP TSA Funding Number: W81XWH 21 PCRP TSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Physician Research Award Apply for W81XWH 21 PCRP PRA Funding Number: W81XWH 21 PCRP PRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CDDRR Capacity Development for Weather, Water, and Climate Forecasting and Disaster Risk Reduction Apply for NOAA NWS NWSPO 2021 2006845 Funding Number: NOAA NWS NWSPO 2021 2006845 Agency: Department of Commerce Category: Science and Technology and other Research and Development Funding Amount: $15,000,000 |
| DoD Prostate Cancer, Data Science Award Apply for W81XWH 21 PCRP DSA Funding Number: W81XWH 21 PCRP DSA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Clinical Consortium Award Apply for W81XWH 21 PCRP CCA Funding Number: W81XWH 21 PCRP CCA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer, Health Equity Research and Outcomes Improvement Consortium Award Apply for W81XWH 21 PCRP HEROICA Funding Number: W81XWH 21 PCRP HEROICA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Convergence Science Research Award Apply for W81XWH 21 PRARP CSRA Funding Number: W81XWH 21 PRARP CSRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award Apply for W81XWH 21 PRARP ADRA Funding Number: W81XWH 21 PRARP ADRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Research Partnership Award Apply for W81XWH 21 PRARP RPA Funding Number: W81XWH 21 PRARP RPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Innovations in Care and Support Award Apply for W81XWH 21 PRARP INCASA Funding Number: W81XWH 21 PRARP INCASA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Peer Reviewed Alzheimer’s, Leveraging Approaches for Innovation in Care and Support Award Apply for W81XWH 21 PRARP LEAP INCASA Funding Number: W81XWH 21 PRARP LEAP INCASA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Racial Equity in STEM Education Apply for PD 21 191Y Funding Number: PD 21 191Y Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Grand Challenges in Integrative Geospace Sciences: Advancing National Space Weather Expertise and Research toward Societal Resilience Apply for 21 577 Funding Number: 21 577 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $2,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 21 PRORP CTRA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.